Isofol Raises 18.9 MSEK via TO1 Warrant Exercise and Directed Share Issue

Isofol Medical AB ( (SE:ISOFOL) ) has issued an announcement.

Isofol Medical has secured approximately 18.9 MSEK in gross proceeds following the exercise of about 93.6% of its series TO1 warrants, each priced at SEK 0.48, resulting in the issuance of 37.3 million new shares. This exercise increases the company’s share capital and brings dilution of roughly 11.7% for shareholders who did not exercise warrants.

Because not all TO1 warrants were exercised, Isofol activated a top guarantee commitment from major shareholder and partner Solasia Pharma K.K., triggering a directed share issue of an additional 2.08 million shares on the same terms as the warrants. The move deepens Solasia’s engagement, lifts total dilution for non-participating shareholders to about 12.3%, and strengthens Isofol’s balance sheet as it continues clinical development of arfolitixorin in colorectal cancer.

The most recent analyst rating on (SE:ISOFOL) stock is a Hold with a SEK0.62 price target. To see the full list of analyst forecasts on Isofol Medical AB stock, see the SE:ISOFOL Stock Forecast page.

More about Isofol Medical AB

Isofol Medical AB is a Swedish clinical-stage biotechnology company focused on improving treatment outcomes for patients with severe cancers. Its lead drug candidate, arfolitixorin, aims to enhance the efficacy of first-line standard therapies for solid tumours and is currently being evaluated in a Phase Ib/II study in colorectal cancer, where there remains substantial unmet medical need.

Average Trading Volume: 1,474,243

Technical Sentiment Signal: Strong Sell

Current Market Cap: SEK179.2M

Learn more about ISOFOL stock on TipRanks’ Stock Analysis page.